Gemcitabine and vinorelbine in advanced non-small cell lung cancer: a phase II trial

Vázquez, Francisca; Baron, F.; Cueva, J; Candamio, Sonia; Calvo, M; Irigoyen, A.; Huidobro, Covadonga; López, Rafael

doi:10.1016/s0169-5002(98)90072-1

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In phase II studies., several authors investigated two schedules of different drug doses. Using both drugs administered on days 1-8-15., recycled every 4 weeks., the response rate ranged from 19 to 72% and MST from 7 to 12 months [125][126][127][128][129][130]; with both drugs administered on days 1-8., recycled every 3 weeks., the response rate varied from 22% to 53% and MST from 8 to 12.6 months [131][132][133][134][135][136][137]. These two schedules have similar activity and toxicity., but the latter 3-week schedule seems to be more manageable.…”

Section: Non-platin-based Combination Chemotherapymentioning

confidence: 99%

“…From this point of view., this dose level seems to be the optimal choice for future phase III trials., being similarly active and less toxic than the other two dose-levels studied. Table 11 summarises gemcitabine plus vinorelbine phase II studies [125][126][127][128][129][130][131][132][133][134][135][136][137]. Overall., noncisplatin-based chemotherapy., and particularly., gemcitabine plus vinorelbine combination., has been shown to be active and well-tolerated in phase II studies., so comparative phase III trials of these drug combination versus cisplatin-based chemotherapy are warranted.…”

Section: Non-platin-based Combination Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Gridelli¹,

Vivo

2002

CMC

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains a fatal disease: the majority of patients are diagnosed as having metastases or advanced inoperable tumors. The activity of chemotherapy in NSCLC patients is low with objective response rarely complete and sustained. Cisplatin-based combinations are considered as the standard chemotherapy treatment. Recently., the introduction of new and less toxic chemotherapeutic agents., such as vinorelbine., has led investigators to research for active non-cisplatin-containing combinations to treat patients with advanced disease having as primary needs symptom relief and an acceptable quality of life. This review will focus on the pharmacological properties of vinorelbine and its role in adjuvant chemotherapy., in combined chemo-radiotherapy., in advanced disease and in the particular setting of the elderly. The oral use of vinorelbine will be among the future developments of this drug.

show abstract